- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02833103
Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction
Application of Pinaverium Bromide in the Treatment of Patients With Post-cholecystectomy Sphincter of Oddi Dysfunction (SOD): A Randomized, Controlled and Multicenter Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
1.1 Background (I)
1.1.1 10%~50% of the patients who previously underwent cholecystectomy experience recurrent abdominal pain with or without diarrhea, abdominal distention, enzymatic changes, etc., and sphincter of Oddi dysfunction (SOD) accounts for about 13% of such cases;
1.1.2 Sphincter of Oddi dysfunction (SOD):
- It refers to biliary kinetic abnormality of the sphincter of Oddi (SO), often accompanied by pain, hepatic and pancreatic enzyme elevation, common bile duct (CBD) dilation or onset of pancreatitis.
- Pain caused by SOD affects the quality of life (QoL).
1.1.3 The diagnosis of SOD is still being disputed, and there has been no optimal solution so far.
- The diagnosis of SOD is largely based on clinical judgment
- The gold standards ERCP and SOM are invasive diagnostic criteria
1.2 Background (II)
1.2.1 If biliary-type abdominal pain after cholecystectomy is considered as SOD, most of the patients are classified as SOD II and SOD III according to Rome III Criteria-modified.
Biliary SOD Type I: moderate or severe biliary-type abdominal pain; transient ALT / AST/ALP elevation > 2ULN; CBD dilation > 8mm as evidenced by ultrasound or other non-invasive examination Type II: biliary-type abdominal pain; One or two of above items Type III:only biliary-type abdominal pain
1.3 Background (III)
1.3.1 Treatment of SOD is being disputed: currently, the main method is to relax sphincter of Oddi (SO).
- Medications: antispasmodic drugs, nitrates, calcium ion antagonists, modulators of gastrointestinal (GI) motility
- EST(endoscopic sphincterotomy): postoperative complications and mortality
1.3.2 EST is not well effective in the treatment of SOD type II and type III, which are mostly caused by functional abnormalities
-ASGE guideline 2015 points out that EST is not recommended for patients with SOD type III. Endoscopic stents are not recommended, either.
1.3.3 Danshu Capsules: contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
1.3.4 Pinaverium Bromide: able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.·10%~50% of the patients who previously underwent cholecystectomy experience recurrent abdominal pain with or without diarrhea, abdominal distention, enzymatic changes, etc., and sphincter of Oddi dysfunction (SOD) accounts for about 13% of such cases.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Zhaohui Tang, MD,PhD
- Phone Number: +86 021 25078999-7905
- Email: tangzhaohui@yahoo.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Recruiting
- Zhang Yong
-
Principal Investigator:
- Xitai Sun, MD,PhD
-
Sub-Investigator:
- Xiaodong Shan, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chief complaint of upper right abdominal pain following LC (within 2 weeks to 6 months) at a hospital visit, but not a pain caused by surgical incision, lasting 3 to 5 minutes each time, without a history of other biliary tract operation
- No presence of intestinal obstruction as evidenced by plain abdominal X-ray, with peptic ulcer and duodenal diverticulum ruled out through barium meal examination or gastroscopy
- No other obvious abnormalities as evidenced by abdominal ultrasound B and MRCP, except for bile duct dilation
- Patients with biliary-type sphincter of Oddi dysfunction (SOD) who are classified as SOD type II (biliary-type abdominal pain accompanied by hepatic enzyme elevation or common bile duct (CBD) dilation) and SOD type III (only biliary-type abdominal pain) according to Geenen-Hogan classification criteria
Exclusion Criteria:
- Postoperative biliary calculi, benign biliary stenosis, bile duct infection, overlong residual cystic duct (> 0.5cm), biliary tumors, etc.
- Peptic ulcer, duodenal diverticulum
- Pancreatitis, pancreatic-type SOD
- Adhesive intestinal obstruction
- Postoperative irritable bowel syndrome (IBS)
- A history of abdominal operation or other surgery
- Pregnant and lactating women
- Use of other drugs from one week after LC to enrollment, including antispasmodic drugs, analgesics, choleretic agents, calcium ion antagonists and GI motility drugs
- A history of allergy to Pinaverium Bromide / Danshu Tablets
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pinaverium Bromide group
Able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.
|
Pinaverium Bromide (100mg potid/day) for three months by oral
Other Names:
|
Active Comparator: Danshu group
Contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
|
Danshu Capsules (0.9g potid/day) for three months by oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Evaluation of Reduction in Abdominal Pain Scores,Change From Baseline to 3 Months After Medication
Time Frame: Change From Baseline to 3 Months After Medication
|
abdominal pain scores (baseline vs. 3 months after treatment)
|
Change From Baseline to 3 Months After Medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Common Bile Duct (CBD) Diameter Measured by Ultrasound B Once a Month
Time Frame: Once a Month, Four Times Totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment)
|
Changes in the CBD diameter measured by ultrasound B
|
Once a Month, Four Times Totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment)
|
Efficacy of Lowering Liver Enzymes as Assessed by Laboratory Test Once a Month
Time Frame: Once a Month, Four Times Totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment)
|
|
Once a Month, Four Times Totally (baseline / 4w after treatment / 8w after treatment / 12w after treatment)
|
Number of Participants With Treatment-Related Diarrhea,Change From Baseline to 3 Months After Medication
Time Frame: From Baseline to 3 Months After Medication
|
The number of patients presenting the symptoms of diarrhea will be calculated at the time of enrollment (baseline) and 3 months after treatment respectively.
|
From Baseline to 3 Months After Medication
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Related Adverse Events as Assessed by Researchers or Doctors Through Study Completion
Time Frame: Through Study Completion, An Average of 1 Year
|
Incidence of adverse events (throughout the treatment)
|
Through Study Completion, An Average of 1 Year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zhaohui Tang, MD,PhD, Xinhua Hospital,School of Medicine,Shanghai Jiao Tong University
- Study Chair: Zhiwei Quan, MD,PhD, Xinhua Hospital,School of Medicine,Shanghai Jiao Tong University
Publications and helpful links
General Publications
- Cotton PB, Durkalski V, Romagnuolo J, Pauls Q, Fogel E, Tarnasky P, Aliperti G, Freeman M, Kozarek R, Jamidar P, Wilcox M, Serrano J, Brawman-Mintzer O, Elta G, Mauldin P, Thornhill A, Hawes R, Wood-Williams A, Orrell K, Drossman D, Robuck P. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA. 2014 May;311(20):2101-9. doi: 10.1001/jama.2014.5220.
- Vitton V, Ezzedine S, Gonzalez JM, Gasmi M, Grimaud JC, Barthet M. Medical treatment for sphincter of oddi dysfunction: can it replace endoscopic sphincterotomy? World J Gastroenterol. 2012 Apr 14;18(14):1610-5. doi: 10.3748/wjg.v18.i14.1610.
- Okoro N, Patel A, Goldstein M, Narahari N, Cai Q. Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis. Gastrointest Endosc. 2008 Jul;68(1):69-74. doi: 10.1016/j.gie.2007.09.046.
- Kalaitzakis E, Ambrose T, Phillips-Hughes J, Collier J, Chapman RW. Management of patients with biliary sphincter of Oddi disorder without sphincter of Oddi manometry. BMC Gastroenterol. 2010 Oct 22;10:124. doi: 10.1186/1471-230X-10-124.
- Behar J, Corazziari E, Guelrud M, Hogan W, Sherman S, Toouli J. Functional gallbladder and sphincter of oddi disorders. Gastroenterology. 2006 Apr;130(5):1498-509. doi: 10.1053/j.gastro.2005.11.063.
- Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. doi: 10.1053/j.gastro.2006.03.008. No abstract available.
- Hernando N, Gisler SM, Reining SC, Deliot N, Capuano P, Biber J, Murer H. NaPi-IIa interacting proteins and regulation of renal reabsorption of phosphate. Urol Res. 2010 Aug;38(4):271-6. doi: 10.1007/s00240-010-0304-3. Epub 2010 Jul 28.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Postoperative Complications
- Biliary Tract Diseases
- Bile Duct Diseases
- Biliary Dyskinesia
- Common Bile Duct Diseases
- Sphincter of Oddi Dysfunction
- Postcholecystectomy Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Bromides
- Pinaverium
Other Study ID Numbers
- XH-16-015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sphincter of Oddi Dysfunction
-
xpgengNot yet recruitingSphincter of Oddi Laxity
-
Peking University Third HospitalUnknown
-
TingBo LiangUnknownHepatolithiasis | Sphincter of Oddi LaxityChina
-
Medical University of South CarolinaCompletedSphincter of Oddi DysfunctionUnited States
-
Cedars-Sinai Medical CenterRecruiting
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedSphincter of Oddi DysfunctionUnited States
-
University of NottinghamCompletedSphincter of Oddi DysfunctionUnited Kingdom
-
Peking University Third HospitalUnknownSphincter of Oddi FunctionChina
-
Gangnam Severance HospitalCompletedPancreatic Diseases | Sphincter of Oddi Dysfunction | Biliary Stricture | Malignant Hepatobiliary Neoplasm | Common Bile Duct StoneKorea, Republic of
-
Wisconsin Center for Advanced ResearchAurora Health CareTerminatedAbdominal Pain | Sphincter of Oddi DysfunctionUnited States
Clinical Trials on Pinaverium Bromide
-
Seoul National University HospitalCompletedCancerKorea, Republic of
-
Changhai HospitalUnknown
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Canada
-
Botanix PharmaceuticalsCompletedPrimary Axillary HyperhidrosisUnited States
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
-
Boehringer IngelheimCompleted
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Canada
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
-
Boehringer IngelheimPfizerCompleted